The FDA drug database lists a supplement dated 2 October 2026 to application NDA 216059 for pirtobrutinib, sold as Jaypirca by Loxo Oncology. The record gives the product and the applicant only. It does not say what the supplement changed, such as a label update, a new indication or a manufacturing change.
A supplement to an existing application is a post-approval change. Without the detail it should not be read as a new indication or a safety communication.
Check the current FDA label before relying on any change. Whether the supplement affects the position of pirtobrutinib in India, including CDSCO status, is not stated in the source.
- The FDA lists a supplement to NDA 216059 for pirtobrutinib, dated 2 October 2026.
- The entry does not say what changed.
- It should not be read as a new indication.
- Check the current FDA label for any change before relying on it.
- CDSCO status is not stated in the source.
Why it matters
Supplement entries are easy to over-read, and this one carries no stated clinical change.
Don't overread it
A licence supplement is not a new indication.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for oncology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free